

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

**VOLUNTARY ANNOUNCEMENT
ENTERING INTO EXCLUSIVE LICENSING AGREEMENT WITH
ROCHE IN RELATION TO SIM0660**

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on September 1, 2026, the Group entered into a licensing agreement (the “**License Agreement**”) with F. Hoffmann-La Roche Ltd (“**Roche**”), pursuant to which, Roche will acquire exclusive global rights to develop, manufacture, and commercialize SIM0660 (CD79a/CD19/CD3 tri-specific antibody), which represents the second asset from the Group’s oncology T-cell Engager (the “**TCE**”) technology platform to be successfully out-licensed, further validating the Group’s innovative strength and global competitive advantage in the TCE technology platform.

Pursuant to the License Agreement, the Group is eligible to receive US\$75 million upfront payment and up to US\$1.455 billion in milestone payments. The Group is also eligible to receive tiered royalties of up to double digits on future net sales.

ABOUT SIM0660

SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its TCE poly-specific antibody technology platform. SIM0660 combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce potent T cell-mediated cytotoxicity while limiting cytokine release. With its potential first-in-class dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide broad coverage across B-cell malignancies, including newly diagnosed and relapsed/refractory disease, and may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies. In addition, SIM0660 also has therapeutic potential for B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company. The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, September 1, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.